康尔诺 康尔诺
康尔诺 康尔诺
Home
About Us
Company Overview Core Team Corporate Culture Qualification Patent Branch Introduction
Products & Services
Product Introduction Research Project
News Center
Company News Industry Trends Technical Literature
Join Us
Talent Philosophy Staff Activities Job Openings
Cooperate
Clinical Research Partnership Opportunities Commissioned Treatment Contact Information
简体中文 English
Home

About Us

Company Overview Core Team Corporate Culture Qualification Patent Branch Introduction

Products & Services

Product Introduction Research Project

News Center

Company News Industry Trends Technical Literature

Join Us

Talent Philosophy Staff Activities Job Openings

Cooperate

Clinical Research Partnership Opportunities Commissioned Treatment Contact Information

进展/死亡风险降 48%！肺癌首个「免疫 + 抗血管」双抗全球数据来了

Source: Industry Trends2025-12-02

Previous

Science子刊详解：临床试验表明靶向GD2的CAR-T细胞有望治疗神经母细胞瘤

Next

This is already the last article

Related Information

Science子刊详解：临床试验表明靶向GD2的CAR-T细胞有望治疗神经母细胞瘤

2022-12-01

Science：利用双特异性抗体靶向癌症

2021-03-11

CMGH：ProAgio药物有望预防胰腺癌和乳腺癌

2021-02-22

Nature子刊论文详解！靶向CXCR5的CAR-T细胞有望治疗滤泡性淋巴瘤和慢性淋巴细胞白血病

2021-01-19

专家点评Cancer Cell丨 砒霜作为p53突变体复活剂，将成为p53突变癌症患者的福音！

2020-12-25

Consultation Hotline

0755-28893318

Address: 深圳市南山区粤海街道高新中一道十号深圳生物孵化基地2#407室

Scan the QR code
Follow the official official account

About Us
Company Overview Core Team Corporate Culture Qualification Patent Branch Introduction
Products & Services
Product Introduction Research Project
News Center
Company News Industry Trends Technical Literature
Join Us
Talent Philosophy Staff Activities Job Openings
Cooperate
Clinical Research Partnership Opportunities Commissioned Treatment Contact Information

Copyright © 2025 深圳市康尔诺生物技术有限公司 粤ICP备09190331号-1

Powered by vancheer